Beta-arrestin 2 is required for lysophosphatidic acid-induced NF-kappaB activation.
about
Multifaceted role of β-arrestins in inflammation and diseaseOverexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progressionPhosphorylation of Thr-516 and Ser-520 in the kinase activation loop of MEKK3 is required for lysophosphatidic acid-mediated optimal IkappaB kinase beta (IKKbeta)/nuclear factor-kappaB (NF-kappaB) activation.GPR54 regulates ERK1/2 activity and hypothalamic gene expression in a Gα(q/11) and β-arrestin-dependent manner.Role of G protein-coupled receptors in inflammation.Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.Distinct and shared roles of β-arrestin-1 and β-arrestin-2 on the regulation of C3a receptor signaling in human mast cells.Endothelin-converting enzyme 1 and β-arrestins exert spatiotemporal control of substance P-induced inflammatory signals.Protein phosphatase 2A acts as a mitogen-activated protein kinase kinase kinase 3 (MEKK3) phosphatase to inhibit lysophosphatidic acid-induced IkappaB kinase beta/nuclear factor-kappaB activation.NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.Application of in utero electroporation of G-protein coupled receptor (GPCR) genes, for subcellular localization of hardly identifiable GPCR in mouse cerebral cortex.Molecular basis of lysophosphatidic acid-induced NF-κB activationThrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosomePhosphorylation of C3a receptor at multiple sites mediates desensitization, β-arrestin-2 recruitment and inhibition of NF-κB activity in mast cellsCARMA3: A novel scaffold protein in regulation of NF-κB activation and diseasesNF-κB signaling pathways regulated by CARMA family of scaffold proteins.Identification of a nuclear localization sequence in β-arrestin-1 and its functional implicationsNeurotensin-induced proinflammatory signaling in human colonocytes is regulated by β-arrestins and endothelin-converting enzyme-1-dependent endocytosis and resensitization of neurotensin receptor 1.Ubiquitin-specific Protease 20 Regulates the Reciprocal Functions of β-Arrestin2 in Toll-like Receptor 4-promoted Nuclear Factor κB (NFκB) Activation.TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation.Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphomaMEKK3 is required for lysophosphatidic acid-induced NF-kappaB activation.Endocytic proteins in the regulation of nuclear signaling, transcription and tumorigenesis.Roles of LPA in ovarian cancer development and progression.β-Arrestins: multifunctional signaling adaptors in type 2 diabetes.Functional signaling biases in G protein-coupled receptors: Game Theory and receptor dynamics.β-Arrestins in the immune systemMolecular biology of atherosclerosis.CARMA3 Is a Host Factor Regulating the Balance of Inflammatory and Antiviral Responses against Viral Infection.TMEM43/LUMA is a key signaling component mediating EGFR-induced NF-κB activation and tumor progression.Regulation of inflammation by β-arrestins: Not just receptor tales.Depletion of β-arrestin2 in hepatic stellate cells reduces cell proliferation via ERK pathway.Tumor necrosis factor receptor-associated factor-6 and ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the phosphorylation and activation of the IkappaB kinase complex in vascular smooth muscle cells.β-arrestin 2 regulates Toll-like receptor 4-mediated apoptotic signalling through glycogen synthase kinase-3β.Molecular Approaches To Target GPCRs in Cancer Therapy.
P2860
Q26785883-F59AA5C7-1698-4EE4-A068-43BE303DDA51Q28483701-5B93EDEB-9E25-402F-B07F-03FAE9ADFA66Q33706949-9F974A2A-4A84-4101-95B2-5D38BBBE0AE7Q33707710-924CF3C2-7188-4A3D-924E-73E6ED288977Q33858841-266FD671-3D38-4579-A1C5-689C75B53EE0Q33862932-76141967-1674-44FB-801E-823A5BDA383EQ33903905-8459BEB7-DFB9-4DF0-AE8D-5FC84A77CBAEQ33931244-6D005EAD-FD99-41D5-9A8F-028E0483E713Q33967150-B9359AC6-5117-49F2-91EC-466B0C9D5B0DQ33985202-3D88FECC-6754-45F7-864C-AF304708734EQ34043023-3262EEAC-D5B0-4A30-85C9-FF54FCCED55BQ34126537-995297E5-F7AE-4333-9C1A-9850F1828F51Q34438768-F344C183-2B27-4061-BC69-2914F5AC0C47Q34450340-4EED323A-14C9-4AF4-B7EE-617DF613054CQ34878582-121DB9E3-496C-42E9-8662-78369CD661DEQ35347919-2F0F8004-92D0-4751-A882-45C05DB06BD1Q35841971-21188E5C-A695-4788-A80B-1812E8155D6CQ35922475-690EF554-F516-4659-BB4E-FB0C5B3F439EQ36755025-16D05BEF-1143-4EAA-9AE7-26FBE1B61E91Q36849465-0BDE97B5-958D-49DA-A3A7-0FB1D97CB2B7Q36907842-CCA57AEF-9A31-4FB8-A100-52F120646240Q37284987-19EEB696-99B9-4E9F-806F-7ABA236C2C8DQ37541507-0D54B876-77DC-443B-8CDC-61F36ADE6268Q37650618-969042C5-5B06-4ED6-A6D2-CDC4EAAB9866Q37810522-EFC0F87B-4505-4486-9C8A-028AE737BDBFQ38017282-E0134105-C554-4759-A8E8-46D8B4B4C55BQ38114223-1DEA8808-9241-4181-94A0-49AF2045904FQ38125279-705B69BA-52E5-4873-9A95-AFC107FDD5CFQ38788570-4ED238C5-8E94-43F6-811D-124CE09276F3Q39089387-24CF2B7D-3AA2-4D35-A86C-8E8F0D9EC44DQ39131811-8FA8C360-8C08-4046-8147-223A790D88B6Q39236344-3A2D2073-27CA-4338-BBA5-DB4CDC79712CQ39675750-7983D9D9-8FCC-4AA1-84DC-6D82D88E6368Q45167801-152B4D2E-D07A-4359-B956-6339E82C4557Q46850333-F31FB848-8F8A-4F42-81D5-C206859B4D39
P2860
Beta-arrestin 2 is required for lysophosphatidic acid-induced NF-kappaB activation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Beta-arrestin 2 is required for lysophosphatidic acid-induced NF-kappaB activation.
@en
type
label
Beta-arrestin 2 is required for lysophosphatidic acid-induced NF-kappaB activation.
@en
prefLabel
Beta-arrestin 2 is required for lysophosphatidic acid-induced NF-kappaB activation.
@en
P2860
P921
P356
P1476
Beta-arrestin 2 is required for lysophosphatidic acid-induced NF-kappaB activation.
@en
P2093
P2860
P304
17085-17090
P356
10.1073/PNAS.0802701105
P407
P577
2008-10-24T00:00:00Z